We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Calcium-Sensing Enzyme May Be Drug Target for Treating Type II Diabetes

By LabMedica International staff writers
Posted on 25 Apr 2012
A recent paper discussed new findings that help to explain how glucose metabolism is regulated in the liver, a subject vital to researchers seeking a cure for diabetes.

Investigators at Columbia University (New York, NY, USA) worked with liver cells growing in culture as well as with a diabetic mouse model. More...
Their goal was to elucidate the underlying molecular mechanisms responsible for glucose production in the liver, which is crucial for glucose homeostasis.

Preliminary results led them to focus their attention on a calcium-sensing enzyme, CaMKII (calcium/calmodulin-dependent protein kinase II). This enzyme appeared to be required for the release of glucose into the blood following binding of glucagon to its receptor.

Glucagon is a hormone secreted by the pancreas that raises blood glucose levels. Its effect is opposite that of insulin, which lowers blood glucose levels. The pancreas releases glucagon when glucose levels fall too low. Glucagon causes the liver to convert stored glycogen into glucose, which is released into the bloodstream. High blood glucose levels stimulate the release of insulin. Insulin allows glucose to be taken up and used by insulin-dependent tissues. Thus, glucagon and insulin are part of a feedback system that keeps blood glucose levels at a stable level.

The investigators reported in the April 12, 2012, online edition of the journal Cell Metabolism that CaMKII dispatched a protein called FoxO1 to the cell nucleus, where it activated the genes needed for glucose secretion. Genetic deficiency or inhibition of CaMKII blocked nuclear translocation of FoxO1 by affecting its phosphorylation, which lowered blood glucose levels, while constitutively active CaMKII had the opposite effect.

“What we have found is a way to reduce glucagon’s influence on blood sugar without the side effects of global glucagon repression,” said senior author Dr. Ira Tabas, professor of anatomy and cell biology at Columbia University. “Even when their disease is well controlled, most patients with type II diabetes have excess glucagon action, so blocking CaMKII could potentially be a new way to lower blood sugar and better treat the disease. Until now, it has been difficult to block glucagon’s effect on blood sugar without interfering with glucagon’s other functions, but we think CaMKII is different.”

Related Links:

Columbia University


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Pipette
Accumax Smart Series
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.